A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Enrolling By Invitation
18-99 years
All
Phase
2
50 participants needed
1 Location
Brief description of study
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-small Cell Lung Cancer,NSCLC
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Diagnosis of Advanced Non-small Cell Lung Cancer (NSCLC)
Updated on
01 Aug 2024.
Study ID: 851171
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
